1. Home
  2. EIC vs NMRA Comparison

EIC vs NMRA Comparison

Compare EIC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • NMRA
  • Stock Information
  • Founded
  • EIC N/A
  • NMRA 2019
  • Country
  • EIC United States
  • NMRA United States
  • Employees
  • EIC N/A
  • NMRA N/A
  • Industry
  • EIC Finance/Investors Services
  • NMRA
  • Sector
  • EIC Finance
  • NMRA
  • Exchange
  • EIC Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • EIC 352.9M
  • NMRA 287.6M
  • IPO Year
  • EIC 2019
  • NMRA 2023
  • Fundamental
  • Price
  • EIC $13.91
  • NMRA $0.65
  • Analyst Decision
  • EIC Strong Buy
  • NMRA Buy
  • Analyst Count
  • EIC 1
  • NMRA 8
  • Target Price
  • EIC $17.50
  • NMRA $9.29
  • AVG Volume (30 Days)
  • EIC 284.8K
  • NMRA 1.2M
  • Earning Date
  • EIC 05-20-2025
  • NMRA 05-06-2025
  • Dividend Yield
  • EIC 17.20%
  • NMRA N/A
  • EPS Growth
  • EIC N/A
  • NMRA N/A
  • EPS
  • EIC 1.97
  • NMRA N/A
  • Revenue
  • EIC $46,223,036.00
  • NMRA N/A
  • Revenue This Year
  • EIC $39.61
  • NMRA N/A
  • Revenue Next Year
  • EIC $27.28
  • NMRA N/A
  • P/E Ratio
  • EIC $7.08
  • NMRA N/A
  • Revenue Growth
  • EIC 72.79
  • NMRA N/A
  • 52 Week Low
  • EIC $12.73
  • NMRA $0.62
  • 52 Week High
  • EIC $16.71
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • EIC 39.38
  • NMRA 22.34
  • Support Level
  • EIC $13.78
  • NMRA $0.64
  • Resistance Level
  • EIC $14.83
  • NMRA $0.83
  • Average True Range (ATR)
  • EIC 0.47
  • NMRA 0.09
  • MACD
  • EIC -0.04
  • NMRA 0.02
  • Stochastic Oscillator
  • EIC 47.77
  • NMRA 6.68

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: